TABLE 1

Biodistribution of 111In-Labeled Tracers (Injected Dose, 3 μg) 4 and 24 Hours After Injection in BALB/c nu/nu Mice Bearing EGFR-Expressing A431 Xenografts

4 h after injection24 h after injection
Organ or tissue111In-Bz-DTPA-ZEGFR:1907111In-Bz-DTPA-ZTaq111In-Bz-DTPA-(ZEGFR:1907)2111In-Bz-DTPA-(Z)2111In-Bz-DTPA-ZEGFR:1907111In-Bz-DTPA-(ZEGFR:1907)2
Blood1.5 ± 0.5*0.03 ± 0.011.5 ± 0.70.037 ± 0.0020.07 ± 0.02*0.07 ± 0.02
Lung1.3 ± 0.2*0.25 ± 0.041.1 ± 0.20.15 ± 0.010.28 ± 0.04*0.5 ± 0.2
Liver5 ± 1*1.4 ± 0.218 ± 50.6 ± 0.21.2 ± 0.3*6 ± 1
Spleen0.7 ± 0.2*0.41 ± 0.061.1 ± 0.20.18 ± 0.030.33 ± 0.04*0.76 ± 0.05
Colon1.2 ± 0.2*0.30 ± 0.051.6 ± 0.50.23 ± 0.050.44 ± 0.08*1.35 ± 0.09
Kidney136 ± 11*189 ± 1973 ± 7207 ± 35102 ± 2*59 ± 7
Tumor3.73 ± 0.08*0.4 ± 0.21.57 ± 0.070.19 ± 0.072.0 ± 0.3*1.23 ± 0.07
Muscle0.29 ± 0.06*0.06 ± 0.010.24 ± 0.070.06 ± 0.040.09 ± 0.02*0.20 ± 0.05
Bone0.5 ± 0.30.3 ± 0.2§0.7 ± 0.20.16 ± 0.100.3 ± 0.20.6 ± 0.2
Brain0.06 ± 0.02*0.004 ± 0.0020.06 ± 0.03NM0.01 ± 0.010.04 ± 0.03
GI tract3.6 ± 0.8*1.0 ± 0.46.0 ± 0.71.0 ± 0.31.2 ± 0.2*6 ± 1
Carcass13 ± 1*3 ± 112 ± 21.8 ± 0.34.9 ± 0.59.6 ± 0.5
  • * Significant difference (P < 0.05, paired t test) between 111In-Bz-DTPA-ZEGFR:1907 and 125I-PIB-ZEGFR:1907.

  • Significant difference (P < 0.05, paired t test) between 111In-Bz-DTPA-(ZEGFR:1907)2 and 125I-PIB-(ZEGFR:1907)2.

  • Significant difference (P < 0.05, unpaired t test) between 111In-Bz-DTPA-ZEGFR:1907 and 111In-Bz-DTPA- (ZEGFR:1907)2.

  • § No significant difference (P > 0.05, unpaired t test) between 111In-Bz-DTPA-ZEGFR:1907 and 111In-Bz-DTPA-ZTaq.

  • Data for gastrointestinal (GI) tract and carcass are presented as %IA per sample.

  • NM = nonmeasureable.

  • Data are presented as average %IA/g and SD (n = 4). Nonspecific Affibody molecules ZTaq and (Z)2 have been included as negative control for 111In-Bz-DTPA-ZEGFR:1907 and 111In-Bz-DTPA-(ZEGFR:1907)2, respectively.